沙美特罗替卡松粉吸入剂治疗中度慢性阻塞性肺疾病稳定期的临床疗效观察

Clinical Effect of Salmeterol Assigned Powder Inhalant on Moderate Stable Chronic Obstructive Pulmonary Disease

目的探究沙美特罗替卡松粉吸入剂治疗中度慢性阻塞性肺疾病稳定期的临床疗效。方法选取2011年4月—2012年12月武汉市武东医院收治的中度慢性阻塞性肺疾病稳定期患者91例,根据入院序列号分为对照组45例和研究组46例。对照组患者给予常规祛痰、平喘治疗,研究组患者在对照组基础上给予沙美特罗替卡松粉吸入剂治疗。比较两组患者治疗前后肺功能指标〔呼气峰值流速（PEF）、用力肺活量（FVC）、第一秒用力呼气容积（FEV1）/FVC〕、圣乔治呼吸问卷（SGRQ）评分（包括症状评分、疾病影响评分、活动评分和总分）。随访1-2年,比较两组患者慢性阻塞性肺疾病急性发作次数。结果治疗前两组患者PEF、FVC、FEV1/FVC比较,差异无统计学意义（P〉0.05）;治疗后研究组患者PEF、FVC、FEV1/FVC均高于对照组（P〈0.05）。治疗前两组患者症状评分、疾病影响评分、活动评分及SGRQ总分比较,差异无统计学意义（P〉0.05）;治疗后研究组患者症状评分、疾病影响评分、活动评分及SGRQ总分均低于对照组（P〈0.05）。全部患者平均随访（1.63±0.12）年,研究组患者慢性阻塞性肺疾病急性发作次数为（0.49±0.13）次,少于对照组的（1.49±0.37）次（P〈0.05）。结论沙美特罗替卡松粉吸入剂治疗中度慢性阻塞性肺疾病稳定期患者的临床疗效确切,能有效改善患者的肺功能,减少慢性阻塞性肺疾病急性发作次数。

Objective To investigate the clinical effect of salmeterol assigned powder inhalant on moderate stable chronic obstructive pulmonary disease. Methods A total of 91 patients with moderate stable chronic obstructive pulmonary disease were selected in the Wudong Hospital of Wuhan from April 2011 to December 2012, and they were divided into control group （ n = 4-5 ） and study group （ n = 46 ） according to visiting sequence. Patients of control group received conventional treatment, such as eliminating phlegm and relieving asthma, while patients of study group received extra salmeterol assigned powder inhalant based on conventional treatment. Lung function index （ including PEF, FVC and FEV1/FVC） and SGRQ score （including symptom score, sickness influence score, activity score and total score） before and after treatment were compared between the two groups, and patients of the two groups were followed up for 1 to 2 years to observe the acute episode times of chronic obstructive pulmonary disease. Results No statistically significant differences of PEF, FVC or FEV1/FVC was found between the two groups before treatment （P 〉 0. 05 ）, while PEF, FVC and FEVJFVC of study group were statistically significantly higher than those of control group after treatment （ P 〈 0.05 ）. No statistically significant differences of symptom score, sickness influence score, activity score or total SGRQ score was found between the two groups before treatment （P 〉 0. 05）, while symptom score, sickness influence score, activity score and total SGRQ score of study group were statistically significantly lower than those of control group （P 〈 0. 05）. The average follow - up time was （ 1.63±0. 12） years, the acute episode times of chronic obstructive pulmonary disease of study group was （0. 49 ±0. 13 ）, was statistically significantly less thanthat of control group of （ 1.49±0. 37） （ P 〈0. 05）. Conclusion Salmeterol assigned powder inhalant has certain clinical effect in treating moderate stable chronic obstructive pulmonary disease, can effectively improve the patients＇ lung function and reduce the acute episode times of chronic obstructive pulmonary disease.